What if AI is implemented in the drug development journey? From the discovery phase to post-marketing surveillance, passing through clinical trials and the marketing authorization milestone, AI can help the whole process to be more streamlined, faster and efficient. However, regulators still need to catch up and address the different challenges and grey zones that the application of the new technologies brings along. This issue points out some recommendations for companies to comply with the current and proposed future legal framework.